# Progress Note 06 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Ada Lovelace (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-NI031-SYN
- Date: 2026-09-08
- Fictional facility: St. Posthumous Health Center
- Fictional author: Constance Whitley-Adeyemi, MD
- Calendar frame: modern shifted

- Visit type: Focused Visit (Follow-up)

## Chief complaint

Fourteen-week review after four cycles: restaging CT, blood counts, iron and thyroid, pain, and goals of care. **S**

## History of present illness

Mrs. Lovelace returns a week after her fourth cycle. The restaging CT a week ago shows a partial response. She has had no bleeding. Her average pain is 3 of 10 on long-acting morphine 15 mg twice a day, now with a breakthrough dose only once or twice a week. She has mild tingling in her toes that does not affect walking or buttons. She tires for three or four days after each cycle. Her bowels are regular on the laxatives. She has no rash, diarrhea, cough, or cold intolerance. She is working most mornings. She has stopped betting and is meeting the social worker about her debts. The thyroid test due six weeks into treatment and the ferritin due after the iron infusions were not drawn; both were drawn today. **S**

| Element | Detail |
|---|---|
| Response | Partial response on CT after four cycles |
| Pain | Average 3 of 10; breakthrough dose once or twice a week |
| Neuropathy | Mild tingling in the toes, no loss of function |
| Work | Mathematics most mornings |
| Missed tests | Six-week thyroid test and ferritin drawn today instead |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Positive | Tired for a few days after each cycle |
| Neurological | Positive | Mild tingling in the toes |
| Endocrine | Negative | No cold intolerance or weight gain |
| Integumentary | Negative | No rash |
| Psychiatric | Negative | Mood better; counseling helps |

5 systems reviewed. **S**

## Current medications

- Morphine sulfate oral solution 2 mg/mL, 5 mg (2.5 mL by oral syringe) every 4 hours as needed for pain **S**
- Morphine sulfate extended-release 15 mg tablet, one tablet by mouth every 12 hours; swallow whole **S**
- Naloxone 4 mg nasal spray, one spray in a nostril for suspected opioid overdose; call 911 **S**
- Senna 8.6 mg tablet, two tablets by mouth at night **S**
- Polyethylene glycol 3350, 17 g in water by mouth once or twice a day **S**
- Acetaminophen 500 mg tablet, two tablets by mouth three times a day **S**
- Pembrolizumab 200 mg intravenously every 3 weeks **S**
- Carboplatin, dose to an AUC of 5 (650 mg), intravenously every 3 weeks for six cycles **S**
- Paclitaxel 175 mg/m2 (275 mg) intravenously every 3 weeks for six cycles, with premedication **S**
- Ondansetron 8 mg tablet, one tablet by mouth twice a day for three days after each chemotherapy cycle, then as needed **S**

## Allergies

- No known allergy **S**

## Objective

BP 112/70 mmHg; pulse 80 bpm; respirations 16/min; temperature 36.7 °C; oxygen saturation 98% on room air; weight 54 kg; BMI 19.8 kg/m². All vital signs are synthetic.

Hemoglobin: 10.6 g/dL (low); White cells: 3.8 10*3/uL (low); Neutrophils: 1.9 10*3/uL; Platelets: 172 10*3/uL; Creatinine: 0.72 mg/dL; ALT: 26 U/L; TSH: 3.4 mIU/L; Ferritin: 210 ng/mL (high); eGFR: 112 mL/min/1.73 m²; Pelvic pain, average over the past week (0 to 10): 3; PHQ-9: 7. All results are synthetic.

## Change since baseline

- Hemoglobin: 8.4 g/dL (low) at baseline, 10.6 g/dL (low) at this visit **S**
- White cells: 7.8 10*3/uL at baseline, 3.8 10*3/uL (low) at this visit **S**
- Platelets: 412 10*3/uL (high) at baseline, 172 10*3/uL at this visit **S**
- Creatinine: 0.68 mg/dL at baseline, 0.72 mg/dL at this visit **S**
- ALT: 18 U/L at baseline, 26 U/L at this visit **S**
- Ferritin: 5 ng/mL (low) at baseline, 210 ng/mL (high) at this visit **S**
- eGFR: 116 mL/min/1.73 m² at baseline, 112 mL/min/1.73 m² at this visit **S**
- Pelvic pain, average over the past week (0 to 10): 7 at baseline, 3 at this visit **S**
- PHQ-9: 8 at baseline, 7 at this visit **S**

## Physical examination

| System | Finding |
|---|---|
| General | Well, not sedated; blood pressure 112/70, pulse 80, weight 54.0 kg |
| Neck | No thyroid enlargement |
| Respiratory | Clear |
| Neurological | Light touch slightly reduced at the toes; vibration and strength normal; grade 1 neuropathy |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Metastatic cervical adenocarcinoma, partial response** (C53.0). CT after four cycles shows a partial response: the cervical tumor 3.1 cm, lung nodules smaller and two gone, para-aortic nodes below 1 cm, no new lesions. Counts allow treatment: white cells 3.8, neutrophils 1.9, platelets 172; creatinine 0.72 mg/dL, ALT 26 U/L. TSH 3.4 mIU/L. Grade 1 neuropathy does not need a dose change. **S**
   - Complete six cycles of carboplatin and paclitaxel, then continue pembrolizumab every 3 weeks.
   - Restaging CT about three months after this one.
   - Report any worsening numbness, which would lead to a paclitaxel dose reduction.
2. **Iron deficiency anemia, iron replete** (D50.0). Hemoglobin 10.6 g/dL without bleeding; ferritin 210 ng/mL, so iron stores are replete; the remaining anemia is from chemotherapy. **S**
   - No further iron; blood count with each cycle.
3. **Cancer-related pelvic pain, controlled** (G89.3). Average 3 of 10 with few breakthrough doses. **S**
   - Continue the current doses; consider tapering if pain stays low after chemotherapy.
4. **Goals of care**. Goals-of-care conversation with Mrs. Lovelace, with the palliative care physician present. She understands that the cancer is responding but cannot be cured. Her hopes are to keep working on her mathematics and to stay at home; her fears are pain and losing her clarity of mind. She wants to continue treatment while it allows that, and she chose not to have resuscitation attempted if her heart stops, while keeping all other treatment. A portable medical order was completed. **S**
   - Share the order with the oncology and palliative care teams.
   - Revisit at each restaging.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Laboratory | Blood count (hemoglobin, white cells, neutrophils, platelets) | Before each chemotherapy cycle and at each visit | Completed today | Hemoglobin 10.6 g/dL, white cells 3.8, neutrophils 1.9, platelets 172 |
| Laboratory | Creatinine, eGFR and ALT | Before each cycle | Completed today | Creatinine 0.72 mg/dL, eGFR 112, ALT 26 U/L |
| Laboratory | TSH and free T4 on pembrolizumab | Baseline, then every 6 weeks | Completed today | TSH 3.4 mIU/L. Protocol deviation: the TSH and free T4 due six weeks after baseline were not drawn, because they were left to be added to the cycle 3 blood tests and were not ordered; drawn today, twelve weeks after baseline. No harm resulted: TSH is normal and she has no thyroid symptoms. Corrective action: a standing order for TSH and free T4 every six weeks while she takes pembrolizumab |
| Laboratory | Ferritin after intravenous iron | 6 to 8 weeks after the infusions | Completed today | Ferritin 210 ng/mL. Protocol deviation: the ferritin due 6 to 8 weeks after the second infusion was not drawn at the preventive visit, which fell in that window; drawn today, twelve weeks after. No harm resulted: stores are replete and hemoglobin is rising. Corrective action: list post-infusion tests on the problem list with their due dates |
| Examination | Vaginal bleeding and transfusion need | Every visit | Completed today | No bleeding |
| Examination | Immune-related adverse effects: rash, diarrhea, cough, fatigue | Every visit | Completed today | None |
| Examination | Peripheral neuropathy on paclitaxel | Before each paclitaxel cycle | Completed today | Grade 1 sensory neuropathy of the toes |
| Imaging | Restaging CT of chest, abdomen and pelvis | Every 2 to 3 cycles during first-line therapy, then every 3 months | Completed today | CT a week ago: partial response |
| Survey | Pain intensity (0 to 10) and function | Every visit | Completed today | Average 3 of 10 |
| Medication safety | Opioid adverse effects: sedation, confusion, nausea | Every visit | Completed today | No sedation |
| Medication safety | Bowel regimen and constipation | Every visit | Completed today | Regular |
| Medication safety | Naloxone, locked storage, one prescriber, prescription monitoring check | At each opioid change, and every 3 months | Completed today | Naloxone in date; locked storage; monitoring check clear |
| Medication safety | Signs of opioid use disorder | Every visit | Completed today | None |
| Survey | Depression screen (PHQ-9) and distress | Periodically | Completed today | PHQ-9 7 |
| Referral | Specialist palliative care | Ongoing alongside cancer treatment | Completed today | Palliative care physician joined today's conversation |
| Self-management | Goals-of-care conversation | At diagnosis, at each restaging, and with any change | Completed today | Recorded; resuscitation not to be attempted; all other treatment continues |

## Goal progress

- Average pelvic pain at or below 3 of 10 without daytime sedation. Outcome by 2026-07-14: Average pain 3 of 10 after radiation, on long-acting morphine, without daytime sleepiness. **S**
- Bleeding controlled and hemoglobin above 10 g/dL without transfusion. Outcome by 2026-09-08: No bleeding since radiation; hemoglobin 10.6 g/dL. **S**
- A documented goals-of-care conversation and a named health care agent. Outcome by 2026-09-08: Advance care plan and goals-of-care conversation recorded. **S**
- Able to work on her mathematics for at least two hours most mornings. In progress; target 2026-10-20. **S**

## Guideline basis

- NCCN Clinical Practice Guidelines in Oncology: Cervical Cancer (2026), National Comprehensive Cancer Network
- Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer (KEYNOTE-826; Colombo N, et al. N Engl J Med 2021;385:1856-1867) (2021), New England Journal of Medicine
- Palliative Care for Patients With Cancer: ASCO Guideline Update (Sanders JJ, et al. J Clin Oncol 2024;42:2336-2357) (2024), American Society of Clinical Oncology
- Use of Opioids for Adults With Pain From Cancer or Cancer Treatment: ASCO Guideline (Paice JA, et al. J Clin Oncol 2023;41:914-930) (2023), American Society of Clinical Oncology
- Patient-Clinician Communication: ASCO Guideline Update (Gilligan T, et al. J Clin Oncol 2026;44:1040-1057) (2026), American Society of Clinical Oncology
- CMID: Clinical Monitoring Intelligence Database, anemia monograph (2026), Aether Forge
- Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update (Schneider BJ, et al. J Clin Oncol 2021;39:4073-4126) (2021), American Society of Clinical Oncology

## Follow-up

- Cycles 5 and 6 every three weeks. Review a week after the last cycle. **S**
- Next scheduled visit 2026-10-20: twenty-week review after the last chemotherapy cycle: blood counts, thyroid on pembrolizumab, tapering morphine, mood and her work. **S**
